The Asia-Pacific Lung Cancer Therapeutics Market is forecasted to worth USD 1.70 billion by 2026 and USD 1.17 billion in 2021, growing at a CAGR of 7.65% from 2021 to 2026. Asia-Pacific countries such as India and China are the developing regions for the global lung cancer therapeutics market due to the high occurrence of this disease and growing healthcare alertness.
The proliferation of lung cancer is primarily driving the APAC market growth. The most significant risk factor for lung cancer is cigarette smoking. Lung cancer can also be caused by prolonged exposure to cigarette smoke. Targeted therapy is a type of cancer treatment that differs from standard chemotherapy. The medicines used in target treatment operate by focusing on specific genes or proteins found in cancer cells. The other factor, such as increasing pollution due to rapid industrialization, is causing lung cancer risk, influencing the market growth. Patients with advanced illness, in particular, have a dismal prognosis, requiring the development of new treatment alternatives. As a result, the NSCLC market shifts away from generic chemotherapy regimens and toward a more complicated treatment landscape based on distinct NSCLC subtypes and molecular aberrations. Over half of all NSCLC cases are detected in those over 65, which is a high-risk age for lung cancer.
The growing awareness among the people about cancer therapeutics in developing countries such as China and India is propelling the market growth in this region. As the region's population ages, the prevalence of lung cancer is expected to rise, providing a revenue boost. An increase in the investment and funding and investments by government and private organizations on research and development of new drugs is expected to uplift the market growth.
Additionally, the adoption of new medical diagnostic Equipment and emerging therapeutics is most likely to increase the market growth. Therefore, the region's key market players focus on constant innovations and product up-gradation and efficient product offering for better treatments and outcomes for the patients.
During the projected period, the immunotherapy sector is predicted to grow at a higher CAGR. The growing number of new product releases, particularly in the immunotherapy sector, is attributed to the market's rise. In addition, immunotherapy is becoming more popular in developing countries due to its more effective treatment, which leads to better patient outcomes.
However, the side effects of drug therapies and the high cost of the therapies have been restraining the market growth.
This research report on the APAC Lung Cancer Therapeutics Market is segmented and sub-segmented into the following categories:
By Treatment Type:
By Country:
Regionally, the APAC is anticipated to account significant share in the global lung cancer therapeutics market. In addition, cigarette smoking has remained common in the Asia-Pacific region. As a result of the growing prevalence of cancer, the market is expected to rise throughout the forecast period. China is estimated to witness the highest share in the market in the forecast period in the regional market. Growing regulatory approvals and adopting advanced therapeutics are more likely to contribute to the highest share. The most prevalent cancers in China include lung, stomach, colorectum, liver, and esophagus. In addition, population expansion, age, environmental pollution, and bad eating habits contribute to an increase in cancer burden and, as a result, cancer treatments.
Also, the Japanese lung cancer therapeutics market is projected to contribute to the APAC regional market growth. New product launches and the prevalence of cancer are expected to escalate the market growth. In addition, the Japanese Ministry of Health, Labor, and Welfare (JMHLW) authorized Keytruda in December 2018 for new indications in advanced, recurrent, or unresectable NSCLC, malignant melanoma, and high microsatellite instability solid tumors. This would help to enhance the company's position in Japan.
The Indian lung cancer therapeutics market is one of the fastest-growing markets in the Asia Pacific over the forecast period. Favorable investments from the government and improving healthcare infrastructure are projected to increase the market growth. In India, F. Hoffmann-La Roche Ltd has introduced Tecentriq, a cancer treatment used for urothelial carcinoma and non-small cell lung cancer (NSCLC). The firm would be able to grow its market in India as a result of this.
KEY MARKET PLAYERS:
A few of the promising companies operating in the APAC Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca plc, and Sanofi-Aventis.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.1.1 Cisplatin
5.1.1.2 Taxol
5.1.1.3 Navelbine
5.1.1.4 Camptosar
5.1.1.5 Alimta
5.1.2 Radiotherapy
5.1.2.1 External Beam
5.1.2.2 Internal Beam
5.1.2.3 Systemic
5.1.3 Other Drugs
5.1.3.1 Abraxane
5.1.3.2 Avastin
5.1.3.3 Crizotinib
5.1.3.4 Docetaxel
5.1.3.5 Gefitinib
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 BoehringerIngelheim GmbH
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Hoffman-La Roche
9.3 Pfizer Inc.
9.4 GlaxoSmitKline
9.5 Eli Lilly and Company
9.6 AstrazenecaPlc
9.7 Sanofi-Aventis
9.8 Agennix AG
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
